ClinicalTrials.gg
CompletedNCT02472535Updated Mar 9, 2016

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

A Phase 2 interventional study of Run-In Period: Placebo and MBX-8025 50 mg (Dose Escalation Period 1) in Homozygous Familial Hypercholesterolemia, sponsored by Gilead Sciences. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-09.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Homozygous Familial Hypercholesterolemia with a site in Canada — 1 open to participants now, 3 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · Canada.

Enrollment
19th of 25
13 · median 29
Started
2015
with 2 others
Phase 2
6 of 28
none open now
Registered
14th of 28
by date

Among the 28 studies in Homozygous Familial Hypercholesterolemia with a site in Canada, this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 6 in phase 2, and was the 14th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

1 of the 28 studies in Homozygous Familial Hypercholesterolemia with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Homozygous Familial Hypercholesterolemia with a site in Canada, or all of them as a file.
02

Study summary

A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Read the detailed description

Open-label, single arm, non-controlled, dose ascending (50 mg/day, 100 mg/day and 200 mg/day) with three consecutive dose escalation periods.

After signing an informed consent subject will enter a screening period and a run-in stabilization period. At the end of run-in period patients will enter treatment phase. MBX-8025 in ascending doses (50 mg, 100 mg, and 200 mg) will be given within three consecutive 4 weeks periods, for a total of 12 weeks. At the end of treatment, subjects will enter a follow-up period.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia

Keywords

  • HoFH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
  2. Male or female with HoFH confirmed by genotype (two mutant alleles at the LDL-Receptor (LDL-R) gene locus or double heterozygotes LDL-R/Apo-B).
  3. 18 years of age or older.
  4. Existing lipid lowering therapies (statins, cholesterol absorption inhibitors, bile acid sequestrants, nicotinic acid and their combinations, low-density lipoprotein (LDL) LDL-C apheresis) on a stable regimen for at least four weeks before screening visit.
  5. Stable lipid lowering diet compatible with a Step I diet of the American Heart Association (AHA).
  6. Fasting LDL-C ≥ 4.8 mmol/L (≥ 185.6 mg/dL) during screening.
  7. For females or males of , use of at least one barrier and a second effective birth control method during the study and for at least two weeks after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with lomitapide or mipomersen within two months of screening.
  2. Heart Failure (HF) with (NYHA) class III and class IV or a (LVEF) of less than 30%.
  3. Uncontrolled cardiac arrhythmia during the past three months of screening.
  4. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke during the past three months of screening.
  5. Planned cardiac surgery, or planned revascularization, in the next four months.
  6. Uncontrolled hypertension.
  7. (AST) or Alanine transaminase (ALT) ≥ 3 times the (ULN).
  8. Unexplained creatine kinase (CK) ≥ 5 times the upper limit of normal (ULN).
  9. For females, pregnancy or breast-feeding.
  10. Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study as judged by the Investigator and/or Medical Monitor.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules

    Other: Run-In Period: Placebo · Drug: MBX-8025 50 mg (Dose Escalation Period 1) · Drug: MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) · Drug: MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)

Interventions

06

What researchers measure

Primary outcomes

  1. LDL-C

    Absolute and percentage (%) reduction in serum LDL-C at any point from baseline through Week 16.

    Time frame: 12-Weeks

Secondary outcomes

  1. Total Cholesterol (TC)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  2. High-density lipoprotein (HDL) cholesterol [HDL-C]

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  3. Very Low-Density Lipoprotein (VLDL)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  4. Non HDL-C

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  5. Remnant-like Particle (RLP-C)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  6. Apolipoprotein B (Apo B)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  7. Apolipoprotein A-I (Apo A-I)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  8. Lipoprotein

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  9. Serum Triglyceride (TG)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  10. Apolipoprotein C-III (Apo CIII)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

Other outcomes

  1. C reactive protein hs-(CRP)

    Absolute and percentage change at any point from baseline through Week 16

    Time frame: 12-Weeks

  2. MBX-8025 Plasma Concentration Levels

    Blood samples for the plasma concentration determination of MBX-8025 and its metabolites (M1, M2 and M3) collected pre-dose at the following visits: 4, 5, 6, 7, 8 and 9.

    Time frame: 12-Weeks

  3. Safety Measures: Number of Participants with Adverse Events as a Measure of Safety

    Complete characterization of Adverse Events (AE), Biochemistry and Hematology

    Time frame: 12-Weeks

  4. Proprotein convertase subtilisin/kexin type 9 (PCSK-9)

    Absolute and percentage change at any point from baseline through Week 16 for the following: Proprotein convertase subtilisin/kexin type 9 (PCSK-9)

    Time frame: 12-Weeks

07

Study locations

5 sites
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • Endocrinologie metabolisme et prevention cardiovasulaire, Institut E3M et IHU cardiometabolique (ICAN), Hôpital Pitié Salpêtrière
    Paris, 75 013, France
  • Radbound UMC
    Nijmegen, 6525 GA, Netherlands
  • Lipidklinikken, Oslo Universitetssykehus
    Oslo, N-0373, Norway
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
Jun 16, 2015
Start
Apr 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Mar 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02472535
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 16, 2015
Start date
Apr 2015
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Mar 9, 2016

Study contacts

Pol F Boudes, M.D.
study chair · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion